Animal and Plant Health Inspection Service, USDA § 113.201

(d) Safety tests. Final container samples of completed product from each serial shall be tested for safety in guinea pigs as prescribed in §113.38 and for safety in mice as prescribed in §113.33: Provided, That, vaccines recommended for use only in poultry are exempt from this requirement.

(e) Viricidal activity test. Only serials tested for viricidal activity in accordance with the test provided in §113.35 and found satisfactory by such test shall be packaged as diluent for decalcified fractions in combination packages.

(f) Formaldehyde content. If formaldehyde is used as the killing agent, the residual free formaldehyde content must not exceed 0.74 grams per liter (g/L) as determined using the ferric chloride test. Firms currently using tests for residual free formaldehyde content other than the ferric chloride test have until July 14, 2004 to update their Outline of Production to be in compliance with this requirement.

§ 113.201 Canine Distemper Vaccine, Killed Virus.

Canine Distemper Vaccine, Killed Virus, shall be prepared from virus-bearing cell culture fluids. Only Master Seed Virus which has been established as pure, safe, and immunogenic shall be used for vaccine production. All serials of vaccine shall be prepared from the first through the fifth passage from the Master Seed Virus.

(a) The Master Seed Virus shall meet the applicable general requirements prescribed in §113.200.

(b) The immunogenicity of vaccine prepared from the Master Seed Virus in accordance with the Outline of Production shall be established. Vaccine used for this test shall be at the highest passage from the Master Seed and prepared at the minimum preinactivation titer specified in the Outline of Production.

(1) Twenty-five canine distemper susceptible dogs (20 vaccinates and 5 controls) shall be used as test animals. Blood samples drawn from each dog shall be individually tested for neutralizing antibody against canine distemper to determine susceptibility. A constant virus-varying serum neutralization test in cell culture using 50 to 300 TCID50 of virus shall be used. Dogs shall be considered susceptible if there is no neutralization at a 1:2 final serum dilution.

(i) The 20 dogs used as vaccinates shall be injected with one dose of vaccine by the method recommended on the label. If a second dose is recommended, the second dose shall be administered at the time specified on the label.

(ii) At least 14 days after the last inoculation, the vaccinates and controls shall each be challenged intracerebrally with canine distemper virus furnished or approved by the Animal and Plant Health Inspection Service and observed each day for 21 days.

(iii) If at least four of the five controls do not die and the survivor, if any, does not show clinical signs of canine distemper, the test is inconclusive and may be repeated.

(iv) If at least 19 of the 20 vaccinated dogs do not survive without showing clinical signs of canine distemper during the observation period, the Master Seed Virus is unsatisfactory.

(c) Test requirements for release. Each serial shall meet the applicable general requirements prescribed in §113.200 and the special requirements for safety and potency provided in this section.

(1) Safety test. The vaccinates used in the potency test in paragraph (c)(2) of this section shall be observed each day during the postvaccination observation period. If unfavorable reactions occur which are attributable to the vaccine, the test is inconclusive and may be repeated: Provided, That, if the test is not repeated, the serial is unsatisfactory.

(2) Potency test—serum neutralization test. Bulk or final container samples of completed product shall be tested for
§ 113.202 Canine Hepatitis and Canine Adenovirus Type 2 Vaccine, Killed Virus.

Canine Hepatitis and Canine Adenovirus Type 2 Vaccine, Killed Virus, shall be prepared from virus-bearing cell culture fluids. Only Master Seed Virus which has been established as pure, safe, and immunogenic shall be used for vaccine production. All serials of vaccine shall be prepared from the first through the fifth passage from the Master Seed Virus.

(a) The Master Seed Virus shall meet the applicable requirements prescribed in §113.200.

(b) Each lot of Master Seed Virus used for vaccine production shall be tested for immunogenicity by one or both of the following methods. Vaccine used for these tests shall be at the highest passage from the Master Seed and prepared at the minimum preinactivation titer specified in the Outline of Production.

(1) Immunogenicity for canine hepatitis. Twenty-five canine hepatitis susceptible dogs shall be used as test animals (20 vaccinates and 5 controls). Blood samples shall be drawn from these animals and individual serum samples tested. The dogs shall be considered susceptible if the results are negative at a 1:2 final serum dilution in a varying serum-constant virus neutralization test using 50 to 300 TCID$_{50}$ of canine adenovirus.

(i) The 20 dogs to be used as vaccinates shall be injected with one dose of vaccine and the remaining five dogs held as controls. If a second dose is recommended, the second dose shall be administered at the time specified on the label.

(ii) Not less than 14 days after the last inoculation, each vaccinate and control shall be challenged intracerebrally with a virulent canine hepatitis virus furnished or approved by the Animal and Plant Health Inspection Service and observed each day for 14 days.

(iii) If at least four of the five controls do not show severe clinical signs if any of the vaccinates show signs or dies of canine distemper, the serial is unsatisfactory.